登录

医疗设备研发商Fractyl Health公布Rejuva®单次给药GLP-1胰腺基因疗法维持体重和改善身体结构的最新临床前数据

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 8

GlobeNewswire 2024-06-24 11:27 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc.

在经过充分验证的饮食诱导肥胖(DIO)小鼠模型中,单次服用Rejuva可以减少脂肪量并改善血糖,Rejuva还可以防止体重和血糖反弹。semaglutide停药后的数据首次证明,Rejuva治疗有可能模拟GLP-1的自然释放。来自马萨诸塞州伯灵顿的胰腺,2024年6月23日(环球通讯社)——Fractyl Health,Inc。

(Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today presented new data from its preclinical Rejuva pancreatic gene therapy program in an oral presentation at the American Diabetes Association (ADA)’s 84th Scientific Sessions in Orlando, FL.

(纳斯达克:GUTS)(以下简称“公司”)是一家代谢治疗公司,专注于开创治疗肥胖症和2型糖尿病(T2D)的新方法,今天在佛罗里达州奥兰多举行的美国糖尿病协会(ADA)第84届科学会议上,在一次口头演讲中,介绍了其临床前Rejuva胰腺基因治疗计划的新数据。

The presentation titled “Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity,” and was chosen as noteworthy and one of eight President’s Select Abstracts at ADA this year. Rejuva is the Company’s adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy program (PGTx), designed to enable durable production of GLP-1 in the pancreas for the treatment of obesity and T2D.

题为“基于单剂量GLP-1的胰腺基因治疗在肥胖小鼠模型中停用Semaglutide后可持久维持身体成分和血糖”的演讲被选为值得注意的演讲,也是今年ADA的八篇总统精选摘要之一。Rejuva是该公司基于腺相关病毒(AAV)的GLP-1胰腺基因治疗计划(PGTx),旨在实现胰腺中GLP-1的持久生产,以治疗肥胖和T2D。

The study presented at ADA compared the effects of a single dose of Rejuva and daily semaglutide treatment on body composition and glycemic parameters in the well-validated mouse model of diet-induced obesity (DIO). It also examined the effects of single-dose Rejuva in the DIO mice after semaglutide was discontinued.

ADA的研究比较了单剂量Rejuva和每日semaglutide治疗对饮食诱导肥胖(DIO)小鼠模型中身体成分和血糖参数的影响。它还检查了停用semaglutide后单剂量Rejuva对DIO小鼠的影响。

“These data demonstrate that Rejuva can durably improve body composition and fasting glucose, compared to or better than semaglutide, by restoring GLP-1 production in a ‘one-and-done’ treatment,” said Harith Rajagopalan, M.D., Ph.D., co-founder.

联合创始人、医学博士哈里斯·拉贾戈帕兰(HarithRajagopalan)说:“这些数据表明,与semaglutide相比或优于semaglutide,Rejuva可以通过“一劳永逸”的治疗恢复GLP-1的产生,从而持久改善身体成分和空腹血糖。”。

推荐阅读

代谢治疗公司Fractyl Health获得FDA IDE批准,开展Revita® Remain-1停用GLP-1类药物后肥胖症患者体重维持的关键性研究

BioSpace 2024-04-01 18:17

6家biotech上市,融资超10亿美元(2024年1月)

药陌 2024-02-20 08:52

肥胖生物技术公司Fractyl Health上市头日股价大跌14.33%

中国制药网 2024-02-05 10:52

GlobeNewswire

9309篇

最近内容 查看更多

Pomerantz律师事务所宣布对CVS Health Corporation和某些官员提起集体诉讼

4 小时前

ARCPOINT宣布拟发行股份用于债务结算

9 小时前

HealthRecon Connect成功实现SOC 2和SOC 3合规性

10 小时前

相关公司查看更多

Fractyl

微创手术疗法及医疗设备研发商

立即沟通

产业链接查看更多